Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Lamivudine increases hyperbilirubinemic risk in patients with severe hepatitis

  • In: Poster presentation
  • At: Seoul (South Korea) (2017)
  • Type: Poster
  • Poster code: POS-HPS-070
  • By: KIM, Sang Geon (Seoul National University, Seoul, Korea, Republic Of)
  • Co-author(s): Sang Geon Kim:
    Young Hee Choi: College of Pharmacy, Dongguk University, Korea, Republic Of
  • Abstract:

    Background

    Lamivudine is effective against hepatitis B virus infection recovering alanine aminotransferase (ALT) to normal ranges through virus eradication. Also, total bilirubin (TB) represents an improvement of liver function from virus infection. Despite its effectiveness, a few case reports raised the possibility that lamivudine causes liver..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses